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Abstract
Homozygosity lor a 677C-+T mutation at the locus that codes for 5,10-methylenetetrahydrofolate reductase (MTHFR), a 
folate-dependent crucial enzyme in homocysteine metabolism, may render the enzyme thermolabile and less active and has been 
associated with increased levels of plasma total homocysteine (tHcy). We assessed whether this mutation was associated with 
increased risk of coronary atherosclerosis and plasma levels of tHcy and furthermore studied whether folate status would modify 
the associations. Data were collected from subjects with substantial coronary atherosclerosis (;>90% occlusion in one and £: 40% 
occlusion in a second coronary artery, referred to as cases, it = 131) or virtually no coronary narrowing (referred to as coronary 
controls, n = 87) and from a population-based control group (n ~ 100), all residing in the Rotterdam area. The Netherlands. Both 
males and females, aged 25-65 years were studied. The frequency of homozygosity for the mutation ( + / + ) in cases (10.0%) di 
not significantly differ statistically from that observed in coronary controls (11.5%, P = 0.71), population-based controls (7.0%, 
/? = 0.43), or combined control groups (9.1%, P «  0.80). In the overall group (as well as in the three subgroups), plasma tf-Icy 
levels, fasting and to a lesser extent after a methionine-loading test, were higher in + / + subjects than in homozygous normal
/ —), whereas heterozygous subjects ( + / — ) had intermediate levels (Ptrend 'VB 0.001). The + /  +
erythrocyte folate levels <790 nmol/1 (population median) had a 77% (95% Cl, 27-144%) higher geometric mean fasting tHcy 
(21.4, /¿mol/1) than those with higher erythrocyte folate (12. j /¿mol/1). The odds ratio (OR) of coronary atherosclerosis for + / +
subjects, with + / and I subjects as the reference group, in analyses with combined control groups, was 1.1 (95% Cl,
0.5 -2.4). The ORs were 2.2 (95% Cl, 0.7 6.8) and 0.6 (95% Cl, 0.2 1.7) among subjects with low and high folate levels, 
respectively. Our study indicates that homozygosity lor the 677C -*■ T MTHFR mutation, especially in combination with low 
folate status, predisposes to high plasma levels of fasting tHcy. However, homozygosity for this mutation, whether or mil in 
combination with low folate status, was not associated with increased risk of coronary artery disease. (O 1997 Elsevier Science 
Ireland Ltd.
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1. Introduction
* Corresponding author.
Elevated plasma total homocysteine (tHcy), an inde­
pendent risk factor for atherosclerotic vascular disease 
[1,2], is partly genetically determined [3,4]. Homocys-
0021-9150/97/$ 17.00 «  1997 Elsevier Science Ireland Ltd. All rights reserved. 
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teine is formed from methionine and is either catabo- 
lized in the vitamin B<,-dependent transsulfuration path­
way or remethylated to methionine. This latter reaction 
is catalyzed by the enzyme methionine synthase, which 
requires 5-methyltetrahydrofolate (5-methyl-THF) as 
substrate and vitamin B12 as cofactor. 5-Methyl-THF is 
formed by the reduction of 5,10-methylene-THF by 
5,10-methylene-THF reductase (MTHFR), which is a 
regulating enzyme in homocysteine metabolism [5]. 
Consequently, deficiencies of MTHFR may result in 
elevation of plasma tHcy.
severe coronary occlusions (referred to as cases) or 
without substantial coronary occlusions (referred to as
coronary were included. control
group was drawn from the general population and 
comprised subjects with no history of cardiovascular 
disease (referred to as population-based controls). Ex­
clusion criteria for all groups were diabetic, renal, 
hepatic, thyroid or gastro-intestinal disease, cancer, al­
cohol or drug abuse and psychiatric illness.
At angiography, projections were made of the major 
coronary vessels using standard catheterization tech-
In 1988, Kang et al. [6,7] discovered a variant of the niques. A team of cardiologists reviewed the projections
MTHFR enzyme, characterized by a specific enzyme 
activity of approximately 50% of the normal activity. 
The enzyme appeared to be thermolabile, providing an 
opportunity to distinguish between this variant and the 
normal enzyme. Furthermore, and others de­
scribed that thermolability of MTHFR was common in 
the normal population (5%), associated with raised 
tHcy levels, and increased risk of coronary artery dis­
ease [8-10]. Recently, a 677C-+T mutation was de­
tected in the MTHFR gene, and homozygosity for this 
mutation was associated with decreased specific enzyme 
activity, increased thermolability, and elevated tHcy 
[11], mainly in subjects with low levels of plasma folate 
[12,13]. Several investigations have now studied 
whether homozygosity for the MTHFR 677C->-T mu­
tation is a risk factor for cardiovascular disease. Three 
studies found a two- to threefold increased risk for 
atherosclerotic vascular disease [14-16], one study 
found a twofold increased risk for thrombotic vascular 
disease [17], but seven other studies observed virtually 
no association or even a slight inverse association be­
tween homozygosity for the mutation and risk of car­
diovascular disease [18,24].
In the present study, we investigated the frequency of 
677C-+T genotype and its association with tHcy levels 
before and after methionine loading in subjects with 
severely occluded coronaries and normal coronaries, 
and in controls from the general population. Since an 
adequate folate status may counterbalance the defective 
production of 5-methyl-THF in subjects with thermo­
labile MTHFR, we also studied the interactive effect of 
genotype and erythrocyte folate status on plasma tHcy 
level and on risk of coronary atherosclerosis.
2. Patients and methods
i . I. Study population
A case-control study was conducted from June 1992 
to June 1994. Cases and one control group were se­
lected from patients aged 25-65 years, who underwent 
coronary angiography in the Zuiderziekenhuis Hospital
and prepared angiography reports. Based on these, a 
trained research nurse selected potential cases and coro­
nary controls. Cases were defined as those having > 
90% occlusion in one and >  40% occlusion in one 
additional coronary artery. Notably, 77.1% of the cases 
had > 70%) occlusion in a second vessel. Coronary 
controls were defined as those having < 50% occlusion 
in only one coronary artery. The majority (79.5%), had 
no substantial coronary narrowing in all three arteries, 
whereas only 5.7% of them had 50%) stenosis in a single 
coronary vessel. Thus, there was a marked contrast 
between cases and coronary controls, reducing the pos­
sibility of disease misclassification.
The conditions that led to angiography were mainly 
angina pectoris, whereas in some coronary controls a 
known valve defect was the reason. A total of 67 
(51.1%) cases and six (6.9%) coronary controls had a 
history of myocardial infarction prior to angiography. 
In the coronary controls, the myocardial infarctions 
were due to coronary spasms or other nonatheroscle- 
rotic causes.
During the period, a total of 2659 patients
underwent coronary angiography. Of these, 2292 were
not included because of over 65 years
(n 1122), coronary occlusion outside ranges of case
in the Netherlands. Subjects with
and control definition (n =  486), or the presence of one 
or more other exclusion criteria. Of the 367 subjects 
that were invited, 353 (96.2%) could be reached and of
222 were willing to participate (131 cases, 91 
coronary controls, response rate of 62.9%). Three of the 
91 coronary controls that had originally participated, 
were excluded from analysis, as their angiography re­
ports mentioned too much coronary narrowing at sec­
ond evaluation (but not enough to be included in the 
study as a case). Furthermore, genotyping was not 
performed for one coronary control subject, leaving 87 
coronary controls for analyses.
We obtained a population-based control group, from 
a register of about 10 000 men previously, randomly, 
sampled from the catchment area of cases for participa­
tion in a cholesterol-lowering trial (which was not 
conducted). Among men with no prior history of car­
diovascular disease or diabetes, a random sample of 
152 were invited for participation. Fifteen could not be
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reached, 14 did not meet the inclusion criteria and 47 
were not interested, leaving 76 study subjects for partic­
ipation (response rate of 61.8%). One participant was 
excluded from analysis because he reported diabetes at 
the interview. Spouses of 45, randomly chosen, male 
participants were invited to participate, of whom 12 
were not eligible, seven were not willing to participate, 
leaving 26 women for participation (response rate of 
78.8%). Thus, a total o f 101 population-based control
was was not
population-
based controls for analyses. All participants gave their 
written informed consent. The study protocol was ap­
proved by the medical ethics committee.
2.2. Blood sampling and examination
At the day of the examinations, venous blood sam­
ples were obtained from all subjects between 08:30 and 
09:30 h, after a 10 -12 h fast. L-methionine (0.1 
body weight) mixed with orange juice was given orally, 
together with a standardized low protein breakfast. 
After breakfast, subjects were interviewed about medi­
cation, smoking habits, alcohol consumption and other 
coronary risk factors. Subjects received a standardized 
low protein lunch and were asked not to consume any 
protein containing foods, like milk, cheese or meat. At 
6 h after methionine administration, a second 
sample was drawn for estimation of plasma tHcy in 
response to methionine provocation. From one popula­
tion-based control subject, we did 
sample after methionine loading.
pressure re* were 11 *e
methionine loading test 
seated after 5 min rest. Height and 
shoes and heavy clothing) were measured in the morn­
ing.
For measurement of whole blood folate, 200 /d of 
EDTA blood was mixed with 4 ml (1:20) freshly pre-
1% (w/v) ascorbic acid solution. The rest of the 
EDTA blood, to be used for measurement of tHcy and 
creatinine in plasma, was placed on ice immediately and 
in the dark, and centrifuged at 4°C within I h. Serum 
was obtained for measurement of total and I
$I
2.3. Biochemical analyses and freno typing
Plasma tFIcy, 'fers to sum of protein-
bound, free oxidized and reduced species of homocys­
teine in plasma, was determined by a modification of 
the method of Refsum et al. [25). Folate in whole blood
by radio immunoassay 
Products Corporation, Dual-count solid phase 
assay) by Mimelab-Ab, Soraker, Sweden. We expressed 
folate concentration per haematoerit, referred to as
erythrocyte folate. Folate values were missing in two 
cases and two coronary controls. Creatinine, total
and HDL cholesterol (after precipitation of 
LDL and VLDL) were determined with enzymatic pho­
tometry.
DNA was obtained from the buffy coat of EDTA 
blood [26] The mutation involves a C to T mutation at 
nucleotide 677, which converts an alanine to a valine 
residue. The alteration creates a 
used for mutation analysis. The method has 
scribed in detail elsewhere [11]. We used the ;
4 was
f anH * •»♦•TO* / to refer to s
homozygous for the mut 
mutation, i 
lively.
f
2.4. Definition o f  variables and statistical analyses
as o f
rization (cases) or on
Current smoking was 
tobacco at the time of a  
day of methionine loading (controls), 
defined as hypertensive with a systolic blood pressure
> 160 mmHg or diastolic blood pressure > 95 111111 Hg, 
or when they were using anti-hypertensive medication. 
Hypercholesterolemia was defined as serum cholesterol
>  6.5 mmol/1 or the use of cholesterol-lowering drugs. 
Differences in age, gender, and various other cardio­
vascular risk factor levels (adjusted for age and gender) 
between cases and each of the two control groups wen 
tested for significance with Student’s /-test for 
ous variables and Pearson s X2 test for frequency mea-
' S . To study frequency
s, we use
cases
*'iwAn’t' ",2 test. Furthermores 7
>) and 95% confidence intervals (CIs) for +  / +
j and / “  s
enee group. We performed these analyses
groups and all controls combined
We compared
in the overall study population and in mips of
jases i ei
s lor tre
I** ^
tested with Student’s t-test, 
formed with linear regression analysis. Calculation of 
ORs and of
were repe by strata of ei folate levels. We 
level (790 nmol/1) of the 
-point for the folate
strata. This cutoff-point would leave us w 
ble statistical power in 
too small to i
s
more met
v ii . P ~v 1 is are for
two-tailed tests.
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Table I
Characteristics and plasma total homocysteine levels
Cases (n — 131) Coronary controls (n =  87) Population controls (» =  100)
Age (years) 52.5 ± 7 .5 48.1 ±8.0* 49.9 ±  6.9**
Gender (% male) 84.7 59.8* 74.0
— » —*  1.  _ "
Body mass index (kg/m2) 26.6 ±  3.0 26.3 ±  3.5 26.0 ±  3.6
Total cholesterol (mmol/1) 6.8 ±  1.4 6.8 ±1 .7 6.7 ± 1 .7
Total/HDL cholesterol 6.8 ±  2.0 6.2 ±  2.4* 6 .0 +  2.7**
Hypercholesterolemic (%) 67.2 62.5 49.5**
J  t  J t a  _ f  _  A l  .
Triglycerides (mmol/1) 2.0 + 1 .3 1.7 ±  1.0* 1.4 +  0.9**
Systolic blood pressure (mmHg) 134+13 133 ±  16 135 ±  14
Diastolic blood pressure (mmHg) 8 1 + 8 79 ± 9 * 82 Hh 8
Hypertensive (%) 83.2 53.4* 16.8**
_  ft .
Pack years 29.8 ±27.1 25.2 ±  20.3* 21.9 ±21 .4**
Alcohol consumption (glasses/day) 0.8 ± 1 .3 1.1 ±  1.7 1.3 ±  1.6**
Fasting tHcy (/¿mo 1/1) 12.7 11.6 11.9
Post-load tHcy (/¿mol/l) 39.4 36.5* 37.3
Increase in tHcy (/¿mol/1) 26.1 24.4 25.1
tHcy, total homocysteine.
* P < 0.05, cases versus coronary control subjects, adjusted for age and gender (with exception o f these variables themselves).
** / ?<0.05, cases versus population-based control subjects, adjusted for age and gender (with exception of these variables themselves).
Tested with Student’s /-test for continuous variables (geometric means are shown for tHcy, mean ±  S.D. are shown for other variables) and 
Pearson’s x 2 test f ° r frequencies. For tHcy, testing was performed with log-transformed variables.
3. Results
3.1. Characteristics and tHcy
3.2. M THFR genotype
Age, gender, coronary risk factors and plasma tHcy 
levels of the cases and the two control groups are 
shown in Table 1. Except for age and gender, all other 
risk factors were adjusted for age and gender. In com­
parison with each of the control groups, cases had a 
statistically significant higher mean age, proportion of 
hypertensive subjects, mean level of total/HDL choles­
terol, mean serum level of triglycerides and mean pack 
years of smoking. In addition, cases had a statistically 
significant higher proportion of males and mean dias- 
tolic blood pressure, compared to coronary controls. 
Furthermore, compared to population-based controls, 
cases has a statistically significant higher proportion of 
hypercholesterolemic subjects and a lower mean alcohol 
consumption. The mean plasma level of creatinine was 
slightly (but not statistically significant) higher in cases 
(data not shown).
Geometric means of age- and sex-adjusted plasma 
levels of tHcy were higher in cases than in any of the 
two control groups (Table 1). However, the difference 
was statistically significant only for post-load tHcy in 
the comparison with coronary controls. To increase 
statistical power, we combined both control groups. 
Cases had 9% higher geometric mean fasting tHcy 
levels (P =  0.02) and 7% higher geometric mean post­
load tHcy levels (P =  0.04) than the combined control 
groups, after adjusting for age and gender. The geomet­
ric mean of increase after loading (i.e. post-load minus 
fasting level), was 6% (P =  0.15) higher in cases relative 
to the combined control groups.
In the total study population, the allele frequency of 
the mutation was 33%. The frequency of homozygosity 
for the mutation ( +  / +  ) in cases (10.0%) did not 
statistically differ significantly from that observed in 
coronary controls (11.5%, P — 0.71), population-based 
controls (7.0%, P =  0.43) or combined control groups 
(9.1%, P = 0.80) (Table 2).
Gender ratio, age, serum creatinine and risk factors 
for coronary artery disease (body mass index, alcohol 
consumption, serum levels of total/HDL cholesterol, 
triglycerides, hypertension and pack years of smoking) 
were not materially nor significantly different statisti­
cally between the genotype subgroups, in any of the 
three study groups, nor in the total study population.
3.3. Levels o f tHcy by M TH F R  genotype
Geometric mean levels of tHcy were highest among
the + 1 +  subjects and lowest among the / sub-
jects. The +  / — individuals had slightly elevated levels,
compared to / subjects (Table 3). This was true
for all three measurements of tHcy, both in cases and 
each of the control groups, with the exception of tHcy 
increase after methionine loading in population-based
mean
was slightly higher in +  / — subjects than in +  / +  
subjects, although both groups had higher geometric
mean levels than I subjects. Ratios of geometric
mean tHcy levels of +  / +  subjects to levels of I
subjects were highest for fasting tHcy and lowest for 
the increase in tHcy after methionine loading; when
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» oTable
Frequencies of MTHFR 
Genotype
Homozygous normal ( — / — ) 
Heterozygous mutant ( +  / —) 
Homozygous mutant ( + / +  )
Cases (h ~  131)
45.0 (59)
45.0 (59)
10.0 (13)
Coronary controls (u = 87)
39.1 (34)
49.4 (43)
11.5 (10)
Population controls (// =  100)
45.0 (45)
48.0 (48) 
7.0 (7)
m- « w m i l i m i t  I
combining all
15.5
were 1.36 (i.e.
11.4) for fasting tHcy, 1.25 (i.e. 44 .2-r-35.4) for
post-load tHcy, and 1.18 (i.e. 27.7 — 23.6) for post-load 
increase in tHcy. In the combined study groups, tests
foriar trend were statistically 
three tHcy measurements.
pack years of smoking) for - f / +  genotype was 1.2 
(95% Cl, 0.5 3.2).
3.5. Effect modification by erythrocyte folate
3.4. MTHFR ge
atherosclerosis
and risk o f  coronar]
Since elevation of tHcy was much more obvious for 
-1- 1 + subjects than +  / — subjects, in accordance with
andother publications [11,16,21], we considered
_1_ i subjects as one reference group (i.e. OR 1.0).
The ORs for +  / -I- genotype were 0.9 (95% Cl, 0.4 
2.0) and 1.5 (95% Cl, 0.6-3.8), with coronary controls 
and population-based controls as referents, respectively. 
When performing analyses with combined control 
groups, the OR for + / +  genotype was 1.1 (95% Cl, 
0.5-2.3). The corresponding multivariate adjusted OR 
(i.e. adjusted for age, gender, body mass index, alcohol
serum of total/HDL
serum creatinine and
Erythrocyte folate did not materially nor statistically 
significantly differ between the genotypes, neither in the 
separate study groups, nor in the pooled study groups 
(data not shown). Using combined data of the entire 
study population, we calculated plasma tHcy levels of 
groups with low and high erythrocyte folate, per geno­
type, as shown in Fig. 1. Geometric mean plasma tHcy 
was higher for the subjects with low compared to those 
with high erythrocyte folate, especially in the + / + 
group. As Fig. 1 is merely a demonstration, Table 4 
shows mean levels of tHcy for individuals with low and 
high folate status in the ■+• / +  group. The relation was 
most evident for fasting tHcy, as shown in Fig. 1 and 
Table 4.
High folate Low folate
Table 3
Geometric mean plasma total homocysteine by MTIIFR genotypes
•1 ' i  f f V T i f r  ¿ . I  V • ? I‘i I - n f - T f  Vt IT«  - o r *  “ I t ’ t * 1  - f m - *  -  »' It » I rn> -> A lc i i tr .  - I  .  a  I I »  I
Cases 
(n =131)
//mol/1
tHcy
Coronary
controls
(n -  87)
controls 
(/; =  100)
> - i , - - * . - . « *  -  —  :  i U .  » »  i . x  . * 1 . . » « i m -  1 4 -  > » > - • » * — .  — —
1  *  “ >  i  i « !■*. t  *■ - a  K  - 1  —  I n  •  ít y * 0 i  r  • ja .- j  - t  ,  , ,  » . l  r > i* iiw M W  v a A . k i  - a  » . t i  ^  * •
»  i h  • j j p  ) H l  i  I  !  v ¿ t - >  M  J» I,
All
(n =  3 18)
---------— h C * *  I». I  I  l - » w — ^  I * .  . s s * - *  « • t . i  .. L J  ••V i**
H-ÎÏ7/W j  W»H(I  ^ 4«^* 10.3 10.9 11.4
1' 1 —• 12.7 11.9** 12,1** I 0 O**ft % *
+  /"I" 16.6 13.1 17.4 15.5***
P -  0.001
Post-load tHcy
— 1— 36.4 34.5 34.7 35.4
-b / — 41.3** 36.8 38.9** 39.2**
+  / + 46.4 42.0*** 43.6 44.2***
P  a  0.00 1
Increase in tl-Icy
— 1— 23.6 23.7 23.6 23.6
+  / -  27.9** 24.4 26.5 26.4**
+  / +  28.4 28.1 25.8 27.7***
P  =  0.002
tHcy, total 
“ Test for linear
** P c 0,05 for ( +  / —) versus ( — / —); *** P < 0 .0 5  for ( + / + )  versus
( ! ■ ! ! ■  1 /  U l i Ml  I/ /*
oa
u
cd
Ë
«MM«
Cl,
60
50
40
30
20
10
0
t  '  1 : r <mT **
« di,: Vi:V..Ä'#
Post-load
Increase
- / -  + / -  + /4* at* j  M *" *f -I- +/■ + /+
Fig. 1. Plasma total homocysteine for genotypes of 6770'~>T
MTHFR mutation, stratified by low and high erythrocyte folate (cut 
off-point 790 nmol/1), in total study population.
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Table 4
Plasma total homocysteine among subjects homozygous for 677C —>T MTHFR mutation, stratified by median eiythiocyte lolate level (790 nmol/1)
Fasting tHcy 
Geometric mean 
Mean +  S.D.
Post-load tHcy 
Geometric mean 
Mean + S.D.
Increase in tHcy 
Geometric mean 
Mean +  S.D.
Low folate (n = 1 3 )
21.4
2 5 .7 +  18.2
51.2 
56.3 +  26.2
28.9 
30.6 +  10.5
Cl, confidence interval.
High folate (n = 17)
a mol/1
12.1 
12.6 +  3.3
39.5 
41.6 +  15.4
26.8 
29.1 +  14.0
Difference in geometric means 
Percent (95% Cl)
77 (27-144%)
30 ( 70%)
8 ( -1 8 -4 2 % )
i m étti
Finally, using combined control groups, we calcu­
lated ORs of coronary atherosclerosis for +  / +  sub-
jects relative to -f / and / subjects, for strata of
low and high erythrocyte folate level. The ORs were 2.2 
(95% Cl, 0.7-6.8) and 0.6 (95% Cl, 0.2-1.7) among 
subjects with low and high folate levels, respectively. 
However, the interaction was not statistically signifi­
cant; the P-value for the interaction term of folate
homocysteine remethylation, whereas increased post­
load tHcy primarily reflects abnormalities in the 
transsulfuration pathway [28,29]. The only other study 
[12] that also studied the relationship of the mutation 
with increase in tHcy after methionine loading (i.e. after 
subtracting fasting level, which in fact is a better reflec­
tion of transsulfuration than absolute post-load tHcy 
level), observed no differences between the genotypes.
status and + / +  genotype was 0.11 and the logistic 
regression model including genotype, folate status and 
the interaction term did not significantly increase the 
log likelihood ratio estimate in comparison to a model 
including only genotype and folate status. The ORs
In contrast with their finding, we observed a statisti­
cally significant 18% higher geometric mean of increase 
in tHcy after methionine loading in +  / 4- subjects
compared to / subjects (Table 3). Whether this is
a chance finding or whether this indicates an effect of
were not materially affected by multivariate adjustment the mutation on homocysteine transsulfuration needs to
for age, gender and other major coronary risk factors, 
but CIs widened substantially.
4. Discussion
In the present investigation, we showed that ho­
mozygosity for the 677C -> T mutation in the M THFR
be determined in future studies.
Other studies have observed that the trend of higher 
tHcy levels among +  / +  subjects was only apparent in 
those with low folate levels in plasma or serum 
[12,13,21]. However, those findings might still have 
been due to an artefact, as +  / +  genotype is associ­
ated with reduced plasma folate concentration (the 
main circulating form of folate in plasma is 5-methyl- 
THF) [13,20,21,27]. As there is still some variation in
activity within the group of +  / -I- subjectsMTHFR
gene was associated with raised plasma tHcy levels, 
particularly when measured in the fasting state. How­
ever, +  / +  genotype was not associated with increased [11,16], it is not unlikely that 4- / +  subjects at the low 
risk o f  severe coronary atherosclerosis. Elevation of end of the range of enzyme activity will have both low 
tHcy in +  / +  subjects was limited to those with ery-
throcyte folate levels below the median of the study 
population. However, we have not been able to prove 
the hypothesis that the combination of +  / +  genotype 
and low folate status infers an increased risk of coro­
nary artery disease.
Our observation of elevation of tHcy levels in +  / +
subjects compared to /
concentrations of plasma folate and high concentra­
tions of tHcy (and those at the high end of enzyme 
activity will vice versa have both high folate and low 
tHcy). We observed no difference in erythrocyte folate 
levels among the various genotypes, but we found a 
dose-response relation between 677C ->■ T genotype and 
plasma tHcy. Furthermore, we observed higher fasting
and +  / — subjects is tHcy levels among subjects with low compared to high
cellular folate status M THFR
supported by other studies [11-14,16,21,27]. In our erythrocyte folate, which is in agreement with results 
study, as well as in others that studied the relation of published by others [30]. Thus, our data suggest that 
the mutation with both fasting and post-load tHcy
levels [11,14,16], the trend was stronger for fasting than 
for post-load levels. These findings support the idea 
that fasting tHcy level is to a large extent determined by
independent as well as interactive relations with plasma 
tHcy. Erythrocyte folate is a measure of tissue folate
A
stores, which reflects the balance between folate intake,
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absorption, metabolism, and utilization [31]. Provided 
that the determinants of folate homeostasis other than 
folate intake are similar within groups of genotype, our 
findings suggest that adequate intake is essential for 
maintaining low tHcy in 4- / 4- subjects. Furthermore, 
our finding of higher post-load increase tHcy levels in 
4- / +  subjects possibly shows that these individuals 
may also benefit from increasing intake of vitamin Bf), 
the coenzyme in the transsulfuration pathway.
Surprisingly, subjects with the 4-/4- genotype did 
not have increased risk of coronary atherosclerosis, 
despite elevated levels of tHcy, which is generally con­
sidered to be an independent risk factor for cardiovas­
cular disease [1]. When including only coronary 
controls in the risk analyses, we observed an OR of 0.9
for 4-/4- genotype, compared to the / _l- /
genotypes. With population-based controls, we esti-
an OR of 1.5, but neither of the ORs was
statistically significant nor did the ORs differ statisti 
cally significantly from each other. There was a fair 
contrast between cases and coronary controls with re­
spect to coronary artery narrowing, but in the coronary 
controls we had no information on the occurrence of 
thrombi leading to angina without coronary artery 
narrowing. Assuming that these were common and 
related to M THFR genotype, this may have attenuated 
the association to some extent. In population-based 
controls, on the other hand, one is never sure about the 
extent of coronary artery narrowing, since these con­
trols may have substantial, although not clinically man­
ifest coronary atherosclerosis. This again may have lead 
to some attenuation of the association. However, the 
type of design we used, i.e. selecting cases and controls 
by extent of coronary narrowing, and additionally 
studying an unselected populationbased control group, 
has been applied by others and both those studies and 
ours have shown positive, independent associations be­
tween plasma tHcy and risk of coronary atherosclerotic 
disease [32.34].
Other epidemiologic studies that estimated risk of
v / I t*
conflicting results. Kluijtmans et al. [16], the first ones 
to report on the association, found an OR of vascular 
disease of 3.1 (95% Cl, 1.0 9.2) for 4-/4- genotype in
Icomparison with +  / — ; 
discrepancy between our present study and their study, 
both conducted in Dutch populations, may be ex­
plained by the fact that they selected young patients, 
with absence of hyperlipoproteinemia, hypertension 
and diabetes mellitus, i.e. individuals that were other­
wise at a low risk of cardiovascular disease. A Japanese
[15], found a statistically significantly, twofold 
increased risk of myocardial infarction for 4- / +  geno­
type. An Irish study [14], showed a statistically signifi­
cantly threefold increased risk of premature coronary 
artery disease. From data o f a study conducted in Italy
[17], we derived an OR of 2.4 (95% Cl, 1.3 4.6) lor 
early onset venous or arterial occlusive disease or 
thrombosis occurring at unusual sites. Adams et al.
[18], in a study of myocardial infarction conducted in
the UK, found an OR of 0.9 (95% Cl, 0.5 1.5). An 
Australian study by Wilcken et al. [24]
ar to ours, comparing p; 
without angiographically documented coronary artery
disease and healthy subjects. They m OR o f 1.0
(95% Cl, 0.6..1.7) for the comparison of subjects w
■'»ase with those with no or
were similar when
coronary
w
severe coronary disease were compared to healthy sub­
jects. A study conducted in the Boston area [23] found 
an OR of myocardial infarction of 1.1 (95% Cl, 0.6 
1.9). Ma et al. [21], in the Physicians’ Health Study, 
observed an OR of myocardial infarction o f 0.8 
Cl, 0.5 -1.3). With data of a study by N arang et al. [ 
conducted in the UK, an OR of coronary heart disease 
of 0.6 (95% Cl, 0.2 -2.1) could be calculated. Findings
of a French [19] in subjects with non-
Canadian
dependent diabetes mellitus yielded an OR of coronary 
heart disease of 0.7 (95% Cl, 0.4-1.2). Finally, w 
data of a study conducted in the US [201. an OR of 0.5 
(95% Cl, 0.3-0.9) for peripheral and 
disease could be calculated (we 
neonates from the control group, 
materially affect the OR).
Summarizing results from the 
ing ours) reported so far, eight of 
increased risk of cardiovascular disease for 4 
type, despite the fact that these subject generally have
sis, about 2 4 /¿mol/l
1 13,16
(f I* / - * • ■ <  A ,
than in // 4 "  I
on a large meta-analysis [1], for 
plasma tHcy an OR of about 1.5 for eardiovasculai *
••'ase would f o  1
compared to others. The majority of studies found an
estimate much than ( i s
included the value of 1.5, and
be totally ruled out as a factor that exerts increased risk 
of cardiovascular disease through tHcy elevation. How­
ever, based on the currently available data, it is cer-
tainly not an important risk factor for cardiovaseulat *
’/vi en
It is not unlikely, however, that the 4 / 4
will only as a
sease in a s
factor for cardiovascular 
ation with a low folate status.
This may explain why positive associations were < 
served in populations where use o f vitamin supplements
#
i isand fortification of
uncommon (i.e. Dutch [16] or Irish population [14]), as
to no assocr in *
[20,21,23], where use of 
sumption of folate
md con
cerei is more common
studies that investigi
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tion of the mutation with risk of cardiovascular disease 
among subgroups of low and high folate intake [23], or
References
plasma folate [21] did not show a significantly positive 
relationship among those with low intake or plasma 
levels of folate either. With our data we were not able 
to prove the hypothesis that +  / 4- genotype is a risk 
factor for coronary atherosclerotic disease among those 
with low erythrocyte folate levels either.
The absence of a positive association between +  / -f 
genotype and risk of coronary heart disease may thus 
indicate that elevated plasma tHcy is not a risk factor 
for cardiovascular disease, but merely a marker of low 
folate status, which for example through prothrombotic 
action confers the actual risk, as recently suggested by 
results from an animal study [35]. Another explanation 
could be that the mutation has a protective effect, that 
mitigates against the adverse effect of elevated plasma 
tHcy. This aspect may need further study.
In conclusion, we have demonstrated a positive inter­
action between the 677C-+T + / +  genotype and low 
erythrocyte folate, resulting in elevated plasma tHcy, 
especially in the fasting state. However, subjects who 
are homozygous for this common mutation, whether or 
not with a low folate status, did not have increased risk 
of coronary atherosclerosis. This absence of an associa­
tion between the mutation and risk of cardiovascular 
disease, also observed in many other studies, either 
indicates that elevation of plasma tHcy is not a risk 
factor for cardiovascular disease, or that the mutation
I?
has a beneficial effect as well, which mitigates against 
the potential harmful effects of tHcy elevation. The
here suggest that increased dietaryresults
folate intake is a means to lower plasma tHcy levels in 
subjects who are homozygous for the M THFR muta­
tion, but subsequent effects on risk of coronary heart 
disease are uncertain.
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